BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing


Background: According to the international criteria for hereditary non-polyposis colorectal cancer (HNPCC) diagnostics, cancer patients with a family history or early onset of colorectal tumours showing high microsatellite instability (MSI-H) should receive genetic counselling and be offered testing for germline mutations in DNA repair genes, mainly MLH1 and MSH2. Recently, an oncogenic V600E hotspot mutation within BRAF, a kinase encoding gene from the RAS/RAF/MAPK pathway, has been found to be associated with sporadic MSI-H colon cancer, but its association with HNPCC remains to be further clarified.

Methods: BRAF-V600E mutations were analysed by automatic sequencing in colorectal cancers from 206 sporadic cases with MSI-H and 111 HNPCC cases with known germline mutations in MLH1 and MSH2. In addition, 45 HNPCC cases showing abnormal immunostaining for MSH2 were also analysed.

Results: The BRAF-V600E hotspot mutation was found in 40% (82/206) of the sporadic MSI-H tumours and 111 HNPCC cases showing abnormal MSH2 immunostaining.

Conclusions: Detection of the V600E mutation in a colorectal MSI-H tumour argues against the presence of a germline mutation in either the MLH1 or MSH2 gene. Therefore, screening of these mismatch repair (MMR) genes can be avoided in cases positive for V600E if no other significant evidence, such as fulfilment of the strict Amsterdam criteria, suggests MMR associated HNPCC. In this context, mutation analysis of the BRAF hotspot is a reliable, fast, and low cost strategy which simplifies genetic testing for HNPCC.

Hereditary non-polyposis colorectal cancer (HNPCC) is perhaps the most common hereditary colon cancer syndrome, accounting for 3–6% of the total colorectal cancer burden.1 These tumours show a particular molecular phenotype in which thousands of mutations within repetitive sequences accumulate throughout the genome of the tumour cells causing high microsatellite instability (MSI-H).2–4 Accumulative data has provided evidence that the underlying event leading to HNPCC is an inherited mutation of a DNA mismatch repair (MMR) gene, mainly MLH1 or MSH2, which account for approximately 90% of the known mutations to date.5–7 Further, mutations in MSH6 account for almost 10% of the cases and a small number of mutations in PMS2 have been also reported in a few cases.7,8 However, mutations in these four MMR genes account for only half of the HNPCC cases identified by pedigree criteria only.9–11 The molecular events causing HNPCC-like pedigrees in which tumours do not have MMR defects is the subject of continued investigation.

The most effective strategy for the diagnosis of HNPCC is the compilation of a thorough family history of colorectal cancer and fulfilment of the Amsterdam criteria.10 However, this information is often not available, about 20% of HNPCC families with germline mutations do not meet these criteria, and further, some colorectal cancer prone families remain mutation negative in MMR gene analyses.11 Because microsatellite instability (MSI) is a hallmark of tumours arising in the HNPCC syndrome,12,13 international criteria have been developed to combine clinical and molecular features to help identify those patients at high risk of a diagnosis of HNPCC.11 Current recommendations include first testing tumours for several of the DNA mismatch repair genes by immunohistochemistry (IHC). Subsequent gene testing can then be targeted to the relevant gene. In this context, available data show that an abnormal immunostaining of MSH2 and MSH6 proteins is most likely the result of germline mutations. When mutations are detected, specific cancer screening and follow up programs are offered to mutation carriers, which have proved profitable in terms of cost-effectiveness when compared to standard care.12–14

Up to this point, it has not been considered cost-effective to perform MSI and/or IHC testing of all unselected patients with colorectal cancer.15 Most sporadic colorectal tumours show no mismatch repair defects and of the 12–15% of unselected colorectal tumours that do demonstrate defective MMR, the MSI-H phenotype is primarily due to hypermethylation of the MLH1 gene promoter,16–18 and not to germline mutations. Thus, it would be desirable to exclude this latter group from further MMR gene testing. However, the age at onset of colorectal cancer in HNPCC might be older than previously thought and further, some HNPCC patients have minimal family history.19 These data suggest that testing of MSI in all colorectal tumours might be considered when population based screenings are performed or whenever possible.

Recently, an oncogenic V600E (previously known as V599E) hotspot mutation in BRAF, a kinase encoding gene from the RAS/RAF/MAPK pathway, has been found in

Abbreviations: HNPCC, hereditary non-polyposis colorectal cancer; IHC, immunohistochemistry; MMR, mismatch repair; MSI, microsatellite instability.
colorectal tumours that show MMR deficiency. Further, it has been shown that these mutations occur almost exclusively in tumours located in the proximal colon and with hypermethylation of MLH1, the gene involved in the initial steps of development of these tumours. However, in more detailed analyses, BRAF mutations were not detected in those cases with or presumed to have a germline mutation in either MLH1 or MSH2. Because of these findings, we have further investigated the role of the BRAF mutation V600E in HNPCC cases harbouring known pathogenic mutations in MLH1 or MSH2. Furthermore, we have investigated whether analysis of the V600E mutation might be used as a primary marker to obviate further genetic testing of MLH1 and MSH2 in HNPCC diagnostics.

METHODS

Tumour specimens
Colon cancers were obtained from the Hospital Universitari Vall d’Hebron (Barcelona, Spain), Groningen University Hospital (Groningen, The Netherlands), Mayo Clinic (Rochester, MN, US), Sapporo Medical University (Sapporo, Japan), Hospital of S. João (Porto, Portugal), Saint-Antoine Hospital (Paris, France), and also from several different hospitals in Finland and Sweden. Sample collection was carried out in accordance with the previously established ethical protocols from each of the participating institutions, and the respective ethics committees approved the study. Collected tumours were either paraffin embedded or immediately frozen in liquid nitrogen for further analyses.

Sporadic colon tumours and MSI analysis
A total of 206 sporadic colorectal tumours with MSI from the available tumour collections were selected for this study. Genomic DNA was extracted with phenol-chloroform according to standard procedures. Further, tumours were analysed for MSI according to the international criteria for the determination of MSI, using various panels of dinucleotide and mononucleotide repeat sequences. All tumours were classified as MSI-H and showed instability in at least 40% of the micro satellites analysed. None of them had a family history suggestive of HNPCC.

HNPCC tumour samples and germline mutation analysis of MLH1 and MSH2

Extensive series of tumours from previously diagnosed HNPCC patients were analysed for germline mutations in the MLH1 and MSH2 genes in each of the institutions involved in this study. DNA was isolated as described above. Analyses were performed using several laboratory routines and mutations verifed by automatic sequencing. In some cases, large deletions of MLH1 and MSH2 were detected by Southern blotting or alternative strategies. A total of 111 HNPCC tumour cases which showed germline mutations of MLH1 or MSH2 were selected for this study. In addition, 45 cases showing abnormal immunostaining for MSH2 were also analysed. Immunohistochemistry for MSH2 was performed as previously described. Although the germline mutation status of these cases was not determined, current available data strongly suggest that these cases are very likely to contain germline mutations in MSH2. These latter cases were referred for tumour analysis (MSI and IHC) because of either a positive family history or early onset of colon cancer.

Mutational analysis of the BRAF-V600E hotspot

Analysis of BRAF was performed by automatic sequencing. The fragment encompassing exon 15 was amplified by PCR in all carcinoma samples. Primer sequences and PCR conditions were based on those reported previously. Genomic DNA (25–100 ng) was amplified by PCR using the following cycling conditions: 30 s at 94°C, 30 s at 60°C, and 45 s at 72°C for 35 cycles. PCR products were purified and sequenced on an ABI Prism 377 Automatic sequencer (Perkin-Elmer, Foster City, CA) using the ABI Prism Dye Terminator Cycle Sequencing Kit (Perkin-Elmer).

RESULTS AND DISCUSSION

Overall, 77 tumours were obtained from a total of 67 HNPCC families showing 37 different germline mutations in MLH1 and 34 tumours accounting for 30 different germline MSH2 mutations were obtained from 33 HNPCC families (table 1). We found the V600E mutation of BRAF in 40% (82/206) of sporadic colon cancer cases showing MSI, which is in agreement with previous reports. However, the V600E mutation was not detected in any of the 111 HNPCC tumours tested nor in any of the 45 additional analysed tumours showing abnormal IHC for MSH2 (table 1), indicating that this hotspot mutation is very rarely if ever involved in the tumourigenesis of colorectal cancer linked to HNPCC.

In contrast to the commonly accepted concept that molecular pathways and genes involved in MSI are identical in HNPCC and sporadic colorectal tumours, these results suggest that genotypic differences might distinguish sporadic and hereditary MMR defective colorectal cancers, although the molecular explanation for such a difference is still to be unravelled.

Accordingly, future analysis of the BRAF-V600E mutation as part of the diagnostic protocols for HNPCC is an encouraging perspective. After completion of our study, however, two BRAF mutations have been reported in two mismatch repair deficient colon tumours showing germline alterations in MLH1 and MSH2. Nonetheless, further analyses of these cases showed that the BRAF mutation seen in the MSH2 tumour was a frameshift mutation caused by an insertion of an adenine within a repetitive sequence of five adenosines and not V600E. In fact, this mutation generates a truncated protein and is most likely a background mutation of the underlying MMR defect. In addition, as stated by the authors, the alteration detected in the MLH1 case was likely to be a non-pathogenic variant. Furthermore, previous reports have shown that the BRAF-V600E mutation is detected in sporadic colorectal tumours with MSI, but only in those cases characterised by promoter hypermethylation of the MLH1 gene, suggesting that mechanisms other than inactivation of the mismatch repair system itself might be modulating the tumourigenic advantage capabilities of the V600E mutation. These data are also in agreement with a recent report by Deng et al suggesting that BRAF might be used in a strategy to detect HNPCC families.

Accordingly, our data suggest that if the V600E mutation is detected in a colorectal MSI-H tumour, further testing for germline mutations in MLH1 or MSH2 should be considered only if other significant findings point towards MMR associated HNPCC, such as fulfillment of the strict Amsterdam criteria. Such caution is necessary because colorectal cancer is a common disease and some cases seen in HNPCC families must arise through pathways not involving germline mutations in the MMR pathway. Furthermore, it is not clear yet whether other DNA mismatch repair genes associated with HNPCC, such as hMSH6, will still need to be testing if BRAF-V600E is detected. In this context, the combination of MSI and IHC analyses provides valuable information. Current data suggest that nearly all HNPCC cases involving MSH2 and MSH6 arise as a consequence of a germline mutation. Thus, identification of these cases by a combination of MSI and IHC is relatively straightforward and highly predictive of a germline alteration. Therefore, germline testing of MSH2 and MSH6 should be considered if IHC demonstrates the involvement of these
genes, regardless of other risk factors (fig 1). On the other hand, because epigenetic inactivation of MLH1 is a common event in approximately 12% of all colon cancers, the predictive value of the absence of protein expression for MLH1 determined by IHC is not perfect. Although IHC for MLH1 is important for identifying the involvement of this gene, the addition of BRAF testing might provide important predictive information. Therefore, if IHC suggests the involvement of MLH1, then the presence of BRAF-V600E suggests that the defective MMR in the tumour is the result of a somatic alteration.

On the other hand, testing of unselected cohorts of colorectal tumours for MSI is currently not recommended by international criteria. Reyes et al. have recently shown that germline testing of individuals who meet the Amsterdam criteria only, results in the detection of the fewest gene carriers at the lowest cost, whereas MSI testing of all colorectal patients, although having the highest cost,
Introduction of BRAF-V600E analysis into testing for germline defects in MLH1 and MSH2 in HNPCC; detection of BRAF-V600E will avoid further testing for germline mutations. The flow chart illustrates the HNPCC diagnostic from unselected cohorts of newly diagnosed tumours analysed for MSI and deems that a positive family history of cancer is always an indication for counselling. **The diagram also considers whether genetic counselling is accepted or not by the patients when offered. We also suggest that in a population with possible founder mutations, whether BRAF or founder mutation analysis is the first choice test should depend on methodological advantage. IHC: immunohistochemistry analyses of MLH1, MSH2, and MSH6 are also recommended. *BRAF is analysed only if tumours are MSI-H or if IHC indicates involvement of MLH1. If IHC indicates involvement of MSH2 or MSH6, analysis of germline mutations of these genes should be the next step. CRC, colorectal cancer.

**Figure 1**

**Table 2** Estimated outcomes from HNPCC testing with and without BRAF-V600E analysis*

<table>
<thead>
<tr>
<th>Using the Bethesda guidelines</th>
<th>Newly diagnosed cases per year: 129 400</th>
<th>1.5 528</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases selected for MSI testing: 20 833</td>
<td>Estimated number of BRAF positive cases: 5043</td>
<td>14 655</td>
</tr>
<tr>
<td>Newly diagnosed HNPCC cases showing MLH1 or MSH2 alterations: 860</td>
<td>Reduction rate in MMR testing by BRAF analysis: 17% (504/2980</td>
<td>2550/100</td>
</tr>
<tr>
<td>Estimated newly diagnosed HNPCC cases showing altered IHC of MSH2: 430</td>
<td>Reduction rate in MMR testing by BRAF after MSH2 IHC: 20% (504/2550</td>
<td>100**</td>
</tr>
<tr>
<td>Positive cases showing MSH-H for MMR tests after MSH2 IHC: 2550</td>
<td>Reduction rate in MMR testing by BRAF after MSH2 IHC: 20% (504/2550</td>
<td>100**</td>
</tr>
<tr>
<td>Number of sporadic MSI-H cases: 1260</td>
<td>Estimated number of BRAF positive cases: 5043</td>
<td>14 655</td>
</tr>
<tr>
<td>Newly diagnosed HNPCC cases: 3483</td>
<td>Reduction rate in MMR testing by BRAF analysis: 17% (504/2980</td>
<td>100**</td>
</tr>
<tr>
<td>HNPCC cases showing altered IHC of MSH2: 1747</td>
<td>Reduction rate in MMR testing by BRAF analysis: 17% (504/2980</td>
<td>100**</td>
</tr>
<tr>
<td>Estimated newly diagnosed HNPCC cases showing altered IHC of MSH2: 873</td>
<td>Positive cases showing MSH-H for MMR tests after MSH2 IHC: 14 655</td>
<td>2550/100</td>
</tr>
<tr>
<td>Positive cases showing MSH-H for MMR tests: 15 528</td>
<td>Number of sporadic MSI-H cases: 12 034</td>
<td>1260</td>
</tr>
<tr>
<td>Total newly diagnosed HNPCC cases: 3483</td>
<td>Estimated number of BRAF positive cases: 48134</td>
<td>14 655</td>
</tr>
<tr>
<td>HNPCC cases showing altered IHC of MSH2: 1747</td>
<td>Reduction rate in MMR testing by BRAF analysis: 33% (4813/14 655 C100)</td>
<td>100**</td>
</tr>
<tr>
<td>Estimated newly diagnosed HNPCC cases showing altered IHC of MSH2: 873</td>
<td>Positive cases showing MSH-H for MMR tests after MSH2 IHC: 14 655</td>
<td>2550/100</td>
</tr>
<tr>
<td>Positive cases showing MSH-H for MMR tests after MSH2 IHC: 14 655</td>
<td>Number of sporadic MSI-H cases: 12 034</td>
<td>1260</td>
</tr>
<tr>
<td>Estimated number of BRAF positive cases: 48134</td>
<td>Reduction rate in MMR testing by BRAF analysis: 31% (4813/14 655 C100)</td>
<td>100**</td>
</tr>
</tbody>
</table>
| Reduction rate in MMR testing by BRAF after MSH2 IHC: 33% (4813/14 655 C100) | **

*Calculations were carried out according to previously published data. The number of cases showing MSI-H when using unselected cohorts of tumours is calculated assuming that 12% of cases will be positive, whereas the total number of HNPCC cases is estimated considering that 2.7% of total tumours will be HNPCC as reported previously. **Assuming that half of the newly diagnosed HNPCC cases show altered MSH2 IHC; the number of sporadic MSI-H cases has been estimated from the total number of MSI-H cases to be tested for MMR defects and the number of HNPCC cases showing MLH1 or MSH2 alterations, assuming that they represent 50% of the total HNPCC cases.

These data suggest that MSI testing should be considered for all colorectal cancers and question the effectiveness of limiting genetic MSI testing only to individuals who fulfill the Bethesda guidelines, even though the main reason for not applying wide MSI testing strategies is the prohibitive cost. However, when unselected cohorts of tumours are analysed for MSI, family history of cancer must be included in the screening protocols for familial cancer because some colorectal cancer families do not show MSI-H. Therefore, counselling and surveillance has to be offered to those patients with a positive family history even if MSI-H is not detected.

Further, utilisation of the BRAF-V600E mutation status allows the detection of most gene carriers. In this context, application of the Bethesda guidelines (selection of high risk individuals for MSI analysis) represents a mixed strategy in terms of costs and sensitivity for HNPCC diagnostics. Nonetheless, calculations from available data reveal that the number of candidate patients to be analysed for MSI and MMR genes could be five times higher if unselected cohorts of colorectal tumours are considered (table 2). Also, the number of newly HNPCC diagnosed cases is doubled when unselected cohorts of tumours are used instead of only those meeting the Bethesda guidelines. Further, it has been recently shown that MSI is a predictive factor of tumour response to 5-fluorouracil and irinotecan drug based chemotherapy in colorectal cancer, suggesting a future use of MSI status for directing colorectal cancer patients towards specific and more effective treatments.

These data suggest that MSI testing should be considered for all colorectal cancers and question the effectiveness of limiting genetic MSI testing only to individuals who fulfill the Bethesda guidelines, even though the main reason for not applying wide MSI testing strategies is the prohibitive cost. However, when unselected cohorts of tumours are analysed for MSI, family history of cancer must be included in the screening protocols for familial cancer because some colorectal cancer families do not show MSI-H. Therefore, counselling and surveillance has to be offered to those patients with a positive family history even if MSI-H is not detected.

Further, utilisation of the BRAF-V600E mutation status might improve the cost-effectiveness of the actual genetic tests for HNPCC (table 2) and we therefore suggest including BRAF screening as a step prior to germline testing of MLH1 in colorectal MSI-H tumours. Further, we also suggest using the same strategy for MSH2 if no immunohistochemistry analysis can be performed previously (fig 1). Accordingly, introduction of the BRAF-V600E test together with IHC analysis of the MMR genes in a decision tree for testing MLH1 and MSH2 in these tumours might provide a reliable, fast, and low cost strategy that will help to simplify the current protocols for HNPCC genetic testing.
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing


J Med Genet 2004 41: 664-668
doi: 10.1136/jmg.2004.020651

Updated information and services can be found at:
http://jmg.bmj.com/content/41/9/664

These include:

References
This article cites 32 articles, 15 of which you can access for free at:
http://jmg.bmj.com/content/41/9/664#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Colon cancer (131)
- Screening (oncology) (234)
- Epidemiology (630)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/